Skip to main content

Clinical trials support unit (CTSU)

The Clinical Trials Support Unit (CTSU) is an operational support unit for academic clinical research into all types of cancer. Certain scientific questions of interest to patients can only be understood by means of academic research. This academic research must comply with all quality standards and legal and regulatory requirements applicable to research. It must also be carried out efficiently.

It is for all these reasons that the Institut Bordet, in a desire to develop and encourage such research, decided to create the CTSU. This unit within the Institution brings together the skills and resources needed to conduct high-level research. The CTSU team is responsible for responding to research questions and evaluating the benefits and risks of drugs and procedures, while always ensuring that the patients participating in the clinical studies are adequately protected. 

https://ctsu.bordet.be

Our team

Director of Research Administration
Marielle Sautois

Head of CTSU Operations
Julie Gaye

Associate Head of CTSU Operations
Magalie Krieguer

Medical team 
Michail Ignatiadis, Academic Trials Promoting Team Leader
Evandro De Azambuja, Head of Medical Support Team

 

03/03/2022

 Scientific publications

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 38

Genomics of metastatic breast cancer

Authors : Geukens T, De Schepper M, Richard F, Maetens M, Van Baelen K, Leduc S, Isnaldi E, Nguyen HL, Bachir I, Vandenberghe E, Van den Bogaert W, Punie K, Neven P, Wildiers H, Floris G, Desmedt C
Year : 2022
Journal : Belgian J Medical Oncology
Volume : 16(1)
Pages : 18-28

Correction to: Combined quality and dose-volume histograms for assessing the predictive value of <sup>99m</sup>Tc-MAA SPECT/CT simulation for personalizing radioembolization treatment in liver metastatic colorectal cancer.

Authors : Levillain H, Burghelea M, Derijckere ID, Guiot T, Gulyban A, Vanderlinden B, Vouche M, Flamen P, Reynaert N
Year : 2021
Journal : EJNMMI Phys
Volume : 8
Pages : 9

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.

Authors : Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, Sotiriou C
Year : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 5607-5618

Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.

Authors : Woff E, Salvatore L, Marmorino F, Genovesi D, Critchi G, Guiot T, Ameye L, Sclafani F, Hendlisz A, Flamen P
Year : 2021
Journal : J Nucl Med